Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antiĀ–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

With Eris Lifesciences Limited's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 30.080946
debtToEquity 75.737000
earningsGrowth 0.416000
revenueGrowth 0.078000
grossMargins 0.748830
operatingMargins 0.267250
trailingEps 28.380000
forwardEps 41.650000

ERIS's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
With ERIS's forward EPS higher than its trailing EPS, the company is expected to be more profitable in the current financial year. This signals confidence in ERIS's growth potential, as improved earnings are forecasted compared to the prior year's performance.

Price projections:

Price projections for ERIS
Price projections for ERIS

Price projections for ERIS have consistently been revised upward, suggesting that analysts are increasingly optimistic about the company's performance. This trend reflects a positive outlook for ERIS's future.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


A recent buy bias from analysts toward ERIS may inspire confidence in investors, who could view the stock as a promising investment. This positive sentiment suggests that ERIS might be an appealing option for those looking to grow their wealth through stock market investments.